Advertisement

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Nov
23
Today In Oncology
Could Opportunistic Salpingectomy Prevent Ovarian Cancer in Postreproductive Women
Large AI Breast Cancer Screening Trial Increases Detection Rate
Addition of Durvalumab to BCG After TURBT for BCG-Naive, High-Risk NMIBC
Geriatric Assessment–Guided Approach to Treatment Intensity in Older Adults With Acute Myeloid Leukemia
Reducing the Barriers to Receiving CAR T-Cell Therapy for Patients With Hematologic Malignancies
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo